Inflammation Supplements Market Size, Share, Growth, Demand, Emerging Trends and Forecast by 2035

The global inflammation supplements market is on a remarkable growth trajectory, poised to more than double in value over the next decade. According to a new market study by Fact.MR, the sector is projected to climb from USD 9.3 billion in 2025 to USD 19.9 billion by 2035, expanding at a robust CAGR of 7.9%. This surge is fueled by rising health consciousness, the prevalence of lifestyle-related disorders, and the demand for natural and plant-based anti-inflammatory solutions.

Market Drivers Fueling Growth

The rise in chronic inflammatory conditions such as arthritis, irritable bowel disease, and cardiovascular disorders is a major driver for the global inflammation supplements industry. Consumers are becoming increasingly aware of the long-term risks of inflammation, not only for joint and gut health but also for metabolic and autoimmune diseases.

For More Insights into the Market, Request a Sample of this Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=1999

In parallel, an increasing number of consumers are turning to dietary supplements as preventive healthcare solutions. Products featuring turmeric, curcumin, omega-3 fatty acids, probiotics, and herbal blends have gained widespread acceptance. The trend is further bolstered by the ongoing shift toward vegan, natural, and clean-label products, catering to younger demographics who value sustainability and plant-based nutrition.

The COVID-19 pandemic also accelerated the uptake of supplements designed to boost immunity and reduce inflammation, leaving a lasting impact on consumer buying habits. As lifestyles continue to shift toward preventive and holistic healthcare, demand for multi-functional supplements targeting gut health, immunity, and inflammation reduction is expected to remain strong throughout the forecast period.

Competitive Landscape

The inflammation supplements market is highly competitive, with established players and new entrants intensifying their focus on innovation, formulation diversity, and global expansion.

Leading brands such as Nature’s Bounty, Herbalife, and Now Foods dominate the market with their wide product portfolios, established trust, and large distribution networks across retail and e-commerce platforms. Their strategies emphasize premium quality sourcing, clinical validation, and broad consumer outreach.

Smaller and emerging players are gaining traction by focusing on niche formulations, such as plant-based omega-3s, PEA-based pain supplements, and multi-functional blends targeting specific conditions like gut inflammation or nerve health. Strategic collaborations, clinical research investments, and aggressive product launches are increasingly defining the competitive dynamics of this rapidly evolving industry.

Browse Full Report: https://www.factmr.com/report/1999/inflammation-supplements-market

Recent Developments Reshaping the Market

The past year has seen a series of pivotal product launches and approvals that underscore the dynamism of the inflammation supplements landscape:

• April 2025 – Rasayanam’s Plant-Based Omega-3: Rasayanam introduced a 100% vegan omega-3 supplement sourced from marine algae, offering EPA and DHA as a sustainable and ethical alternative to fish oil. This innovation caters to vegetarians and vegans seeking high-quality plant-based nutrition.
• June 2025 – Amway India’s Nutrilite Triple Protect: Amway launched Nutrilite Triple Protect, a plant-based formulation enriched with Acerola Cherry, Turmeric, and Licorice, designed to enhance immunity, reduce inflammation, and protect gut, skin, and immune health. This highlights the growing consumer preference for herbal blends with multi-functional benefits.
• August 2025 – Arialief’s Sciatic Nerve Pain Supplement: Arialief rolled out a nutritional supplement targeting nerve health using ingredients such as PEA and magnesium glycinate. The product is now available across major markets including the U.S., UK, Canada, New Zealand, and Australia, marking a significant development in condition-specific supplementation.
• June 2024 – AbbVie’s SKYRIZI Approval: Pharmaceutical giant AbbVie secured FDA approval for SKYRIZI (risankizumab-rzaa) to treat moderately to severely active ulcerative colitis in adults. This milestone further reinforces AbbVie’s leadership in inflammatory bowel disease therapies and highlights the convergence of nutraceuticals and pharmaceuticals in addressing inflammation-related conditions.

These developments illustrate the dual approach being adopted by the industry—nutritional supplements for preventive care and pharmaceutical therapies for clinical management—both of which reinforce the significance of inflammation as a central health concern.

Outlook

The inflammation supplements market is projected to experience sustained momentum as preventive healthcare, plant-based innovations, and immune health continue to dominate consumer priorities. With strong growth prospects, leading companies are expected to intensify their focus on R&D, ingredient transparency, clinical validation, and e-commerce expansion to capture market share.

Furthermore, the alignment of supplements with broader wellness and lifestyle trends—such as vegan diets, functional foods, and personalized nutrition—will ensure that inflammation-targeting products remain central to the wellness revolution. Emerging markets in Asia-Pacific and Latin America are also expected to contribute significantly to the industry’s expansion, driven by rising disposable incomes and growing awareness of preventive health solutions.